Liver, kidney, and thoracic organ transplantation under FK 506

S. Todo, J. J. Fung, T. E. Starzl, A. Tzakis, A. J. Demetris, R. Kormos, Ashokkumar Jain, M. Alessiani, S. Takaya, R. Shapiro

Research output: Contribution to journalArticle

194 Citations (Scopus)

Abstract

The new immunosuppressive drug FK 506 was used from the outset with low doses of prednisone to treat 120 recipients of primary liver grafts and 20 more patients undergoing liver retransplantation. The patient survival rate after 2 to 8 months in the primary liver transplantation series is 93.3%, with original graft survival of 87.5%. Of the 20 patients in the hepatic retransplant series, 17 (85%) are living. Almost all of the surviving patients have good liver function. In addition 11 hearts, 2 double lungs, and a heart-lung have been transplanted under FK 506, with survival of all 14 patients. With all of the organ systems so far tested, including the kidney (which has been reported elsewhere), rejection usually has been controlled without additional drugs and with lower average steroid doses than in the past. Nephrotoxicity has been observed, but not to an alarming degree, and there has been a notable absence of hypertension. There is a suggestion that serum cholesterol may be lowered by FK 506, but this is unproved. Although the adverse reactions of FK 506 and the immunosuppressive mechanisms resemble those of cyclosporine, our preliminary observations suggest that FK 506 may have a more advantageous therapeutic index.

Original languageEnglish (US)
Pages (from-to)295-307
Number of pages13
JournalAnnals of Surgery
Volume212
Issue number3
StatePublished - Oct 3 1990

Fingerprint

Tacrolimus
Organ Transplantation
Thorax
Kidney
Liver
Immunosuppressive Agents
Lung
Graft Survival
Prednisone
Pharmaceutical Preparations
Liver Transplantation
Cyclosporine
Survival Rate
Steroids
Cholesterol
Hypertension
Transplants
Survival
Serum

All Science Journal Classification (ASJC) codes

  • Surgery

Cite this

Todo, S., Fung, J. J., Starzl, T. E., Tzakis, A., Demetris, A. J., Kormos, R., ... Shapiro, R. (1990). Liver, kidney, and thoracic organ transplantation under FK 506. Annals of Surgery, 212(3), 295-307.
Todo, S. ; Fung, J. J. ; Starzl, T. E. ; Tzakis, A. ; Demetris, A. J. ; Kormos, R. ; Jain, Ashokkumar ; Alessiani, M. ; Takaya, S. ; Shapiro, R. / Liver, kidney, and thoracic organ transplantation under FK 506. In: Annals of Surgery. 1990 ; Vol. 212, No. 3. pp. 295-307.
@article{bf5b33b12e2e4973b0ba540a9538c8b9,
title = "Liver, kidney, and thoracic organ transplantation under FK 506",
abstract = "The new immunosuppressive drug FK 506 was used from the outset with low doses of prednisone to treat 120 recipients of primary liver grafts and 20 more patients undergoing liver retransplantation. The patient survival rate after 2 to 8 months in the primary liver transplantation series is 93.3{\%}, with original graft survival of 87.5{\%}. Of the 20 patients in the hepatic retransplant series, 17 (85{\%}) are living. Almost all of the surviving patients have good liver function. In addition 11 hearts, 2 double lungs, and a heart-lung have been transplanted under FK 506, with survival of all 14 patients. With all of the organ systems so far tested, including the kidney (which has been reported elsewhere), rejection usually has been controlled without additional drugs and with lower average steroid doses than in the past. Nephrotoxicity has been observed, but not to an alarming degree, and there has been a notable absence of hypertension. There is a suggestion that serum cholesterol may be lowered by FK 506, but this is unproved. Although the adverse reactions of FK 506 and the immunosuppressive mechanisms resemble those of cyclosporine, our preliminary observations suggest that FK 506 may have a more advantageous therapeutic index.",
author = "S. Todo and Fung, {J. J.} and Starzl, {T. E.} and A. Tzakis and Demetris, {A. J.} and R. Kormos and Ashokkumar Jain and M. Alessiani and S. Takaya and R. Shapiro",
year = "1990",
month = "10",
day = "3",
language = "English (US)",
volume = "212",
pages = "295--307",
journal = "Annals of Surgery",
issn = "0003-4932",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

Todo, S, Fung, JJ, Starzl, TE, Tzakis, A, Demetris, AJ, Kormos, R, Jain, A, Alessiani, M, Takaya, S & Shapiro, R 1990, 'Liver, kidney, and thoracic organ transplantation under FK 506', Annals of Surgery, vol. 212, no. 3, pp. 295-307.

Liver, kidney, and thoracic organ transplantation under FK 506. / Todo, S.; Fung, J. J.; Starzl, T. E.; Tzakis, A.; Demetris, A. J.; Kormos, R.; Jain, Ashokkumar; Alessiani, M.; Takaya, S.; Shapiro, R.

In: Annals of Surgery, Vol. 212, No. 3, 03.10.1990, p. 295-307.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Liver, kidney, and thoracic organ transplantation under FK 506

AU - Todo, S.

AU - Fung, J. J.

AU - Starzl, T. E.

AU - Tzakis, A.

AU - Demetris, A. J.

AU - Kormos, R.

AU - Jain, Ashokkumar

AU - Alessiani, M.

AU - Takaya, S.

AU - Shapiro, R.

PY - 1990/10/3

Y1 - 1990/10/3

N2 - The new immunosuppressive drug FK 506 was used from the outset with low doses of prednisone to treat 120 recipients of primary liver grafts and 20 more patients undergoing liver retransplantation. The patient survival rate after 2 to 8 months in the primary liver transplantation series is 93.3%, with original graft survival of 87.5%. Of the 20 patients in the hepatic retransplant series, 17 (85%) are living. Almost all of the surviving patients have good liver function. In addition 11 hearts, 2 double lungs, and a heart-lung have been transplanted under FK 506, with survival of all 14 patients. With all of the organ systems so far tested, including the kidney (which has been reported elsewhere), rejection usually has been controlled without additional drugs and with lower average steroid doses than in the past. Nephrotoxicity has been observed, but not to an alarming degree, and there has been a notable absence of hypertension. There is a suggestion that serum cholesterol may be lowered by FK 506, but this is unproved. Although the adverse reactions of FK 506 and the immunosuppressive mechanisms resemble those of cyclosporine, our preliminary observations suggest that FK 506 may have a more advantageous therapeutic index.

AB - The new immunosuppressive drug FK 506 was used from the outset with low doses of prednisone to treat 120 recipients of primary liver grafts and 20 more patients undergoing liver retransplantation. The patient survival rate after 2 to 8 months in the primary liver transplantation series is 93.3%, with original graft survival of 87.5%. Of the 20 patients in the hepatic retransplant series, 17 (85%) are living. Almost all of the surviving patients have good liver function. In addition 11 hearts, 2 double lungs, and a heart-lung have been transplanted under FK 506, with survival of all 14 patients. With all of the organ systems so far tested, including the kidney (which has been reported elsewhere), rejection usually has been controlled without additional drugs and with lower average steroid doses than in the past. Nephrotoxicity has been observed, but not to an alarming degree, and there has been a notable absence of hypertension. There is a suggestion that serum cholesterol may be lowered by FK 506, but this is unproved. Although the adverse reactions of FK 506 and the immunosuppressive mechanisms resemble those of cyclosporine, our preliminary observations suggest that FK 506 may have a more advantageous therapeutic index.

UR - http://www.scopus.com/inward/record.url?scp=0025004379&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025004379&partnerID=8YFLogxK

M3 - Article

C2 - 1697743

AN - SCOPUS:0025004379

VL - 212

SP - 295

EP - 307

JO - Annals of Surgery

JF - Annals of Surgery

SN - 0003-4932

IS - 3

ER -

Todo S, Fung JJ, Starzl TE, Tzakis A, Demetris AJ, Kormos R et al. Liver, kidney, and thoracic organ transplantation under FK 506. Annals of Surgery. 1990 Oct 3;212(3):295-307.